A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

Ignacio Javier Ansotegui , Giovanni G. Melioli , Giorgio Walter Canonica , René Maximiliano Gómez , Erika Jensen-Jarolim , Motohiro Ebisawa , Olga Luengo , Luis R. Caraballo , Giovanni G. Passalacqua , Lars Kærgaard Poulsen , Eleonora Savi , Torsten Zuberbier , Elisa Villa , John J. Oppenheimer , Riccardo Asero , Jonathan A. Bernstein , Jean J. Bousquet (1, 2, 3) , Victoria Cardona , Linda S. Cox , Pascal M. Demoly (4, 5) , Fátima D. Ferreira , Pedro F. Giavina Bianchi , Sandra Nora Gonzalez Diaz , Thilo Jakob , Luciana Kase Tanno (4, 1, 6) , Jörg Kleine-Tebbe , Michael E. Levin , Bryan L. Martin , Paolo Maria Matricardi , Olga Patricia Monge Ortega , Mário A. Morais Almeida , Carlos Nunes , José António Ortega Martell , Ruby Pawankar , Harald E. Renz , Nelson Augusto Rosário Filho , Philip W. Rouadi , Alessia Ruiba , Hugh A. Sampson , Mario M. Sánchez Borges , Enrico Scala , Peter D. Schmid-Grendelmeier , Gianenrico Senna , Juan Carlos Sisul , Mimi L.K. Tang , Rudolf Valenta , Marianne van Hage , Gary W.K. Wong , Anahí Yáñez

1 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
2 INSERM - Institut National de la Santé et de la Recherche Médicale
3 UVSQ - Université de Versailles Saint-Quentin-en-Yvelines
4 SU - Sorbonne Université
5 Hôpital Arnaud de Villeneuve [CHRU Montpellier]
6 USP - Universidade de São Paulo = University of São Paulo

Precision allergy molecular diagnostic applications (PAMD@) is increasingly entering routine care. Currently, more than 130 allergenic molecules from more than 50 allergy sources are commercially available for in vitro specific immunoglobulin E (sIgE) testing. Since the last publication of this consensus document, a great deal of new information has become available regarding this topic, with over 100 publications in the last year alone. It thus seems quite reasonable to publish an update. It is imperative that clinicians and immunologists specifically trained in allergology keep abreast of the new and rapidly evolving evidence available for PAMD@. PAMD@ may initially appear complex to interpret; however, with increasing experience, the information gained provides relevant information for the allergist. This is especially true for food allergy, Hymenoptera allergy, and for the selection of allergen immunotherapy. Nevertheless, all sIgE tests, including PAMD@, should be evaluated within the framework of a patient's clinical history, because allergen sensitization does not necessarily imply clinical relevant allergies.

Mots clés: Cross reactivity; Diagnosis; Molecular allergy; Panallergen; Specific IgE; PAMD@

Domaines: Allergologie

Ignacio Javier Ansotegui, Giovanni G. Melioli, Giorgio Walter Canonica, René Maximiliano Gómez, Erika Jensen-Jarolim, et al.. A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020. World Allergy Organization Journal, 2020, 13 (2), pp.100091. ⟨10.1016/j.waojou.2019.100091⟩. ⟨hal-03227900⟩